Ribociclib manufacturers

About ribociclib

Ribociclib manufacturers are currently limited to the originator, Novartis, which sells it as Kisqali, while generic companies such as MSN and Fresenius Kabi have settled US patent cases on confidential terms. Ribociclib is an oral CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. It is approved for advanced breast cancer and, since 2024, for early breast cancer at high risk of recurrence. Pharmaceutical companies can prepare ribociclib tablet and API dossiers for launch after patent expiry.

Ribociclib key facts

Ribociclib manufacturers and licensing history

Novartis developed ribociclib with Astex Therapeutics. The FDA approved Kisqali on 13 March 2017 for advanced breast cancer, together with a co-pack containing letrozole. The MONALEESA trials showed longer overall survival in advanced disease.

In September 2024, the FDA approved ribociclib for early breast cancer at high risk of recurrence, based on the NATALEE trial, and the EU followed later in 2024. This greatly expanded the number of eligible patients.

Several generic companies, including MSN and Fresenius Kabi, filed ANDAs challenging Kisqali patents. Novartis settled these cases on confidential terms, so the US generic launch date has not been published. Buyers should confirm the API salt and crystal form, GMP status and freedom to operate before choosing a dossier partner.

Ribociclib dosage forms and dossier types

Ribociclib is approved as 200 mg film-coated tablets, and in the US as a co-pack with letrozole.

Ribociclib regulatory and patent status

The FDA approved ribociclib on 13 March 2017, and for high-risk early breast cancer in September 2024. Novartis settled US patent cases with MSN and Fresenius Kabi on confidential terms. Patent databases estimate the last US patent expires in April 2036. Check the FDA Orange Book and national registers before planning a launch.

Ribociclib mechanism of action and therapeutic use

Ribociclib blocks CDK4 and CDK6, enzymes that drive cancer cells into the next phase of cell division. This stops the growth of hormone receptor-positive breast cancer cells. Ribociclib is taken once daily for 21 days followed by 7 days off, together with endocrine therapy. ECG and liver monitoring are needed, because it can prolong the QT interval and affect the liver.

Ribociclib licensing and sourcing

Ribociclib suppliers and licensing partners typically offer dossier development, API supply or technology transfer, timed for patent expiry. Buyers usually compare GMP status, oncology manufacturing capability, patent position and territory availability. Current offers and supplier contacts are listed among the ribociclib manufacturers on Pipelinepharma.

Frequently asked questions about ribociclib

Who manufactures ribociclib? Novartis is the only manufacturer in the US and EU and sells ribociclib as Kisqali.

When can generic ribociclib launch in the US? Novartis has settled with generic companies on confidential terms, so the launch date has not been published. Patent databases estimate the last patent expires in April 2036.

What is ribociclib used for? Ribociclib is used for HR-positive, HER2-negative breast cancer, in both advanced disease and high-risk early disease.

What forms and strengths of ribociclib are available? Ribociclib is available as 200 mg tablets and, in the US, as a co-pack with letrozole.

How is ribociclib different from abemaciclib? Both are CDK4/6 inhibitors. Ribociclib is taken for three weeks followed by one week off, while abemaciclib is taken continuously.